Comprehensive Market Report: Global Oncology-Focused In Vivo Contract Research Organization (CRO) Market
Executive Summary
The global Oncology-Focused In Vivo CRO market is a critical and high-growth segment within the pharmaceutical and biotechnology R&D outsourcing landscape. These specialized CROs provide indispensable preclinical services using animal models to evaluate the efficacy, safety, and pharmacokinetics of novel cancer therapeutics. The market, valued at an estimated USD XX billion in 2025, is projected to reach approximately USD YY billion by 2036, expanding at a robust Compound Annual Growth Rate (CAGR) of Z% from 2026 to 2036. This growth is propelled by the relentless expansion of the oncology drug pipeline, the rising complexity of novel modalities (e.g., cell & gene therapies, bispecifics, ADCs), and biopharma's strategic focus on outsourcing to access specialized expertise, reduce fixed costs, and accelerate development timelines. This report provides a strategic analysis of service segments, model sophistication, and competitive dynamics.
1. Segments Analysis
By Service Type:
-
Pharmacology & Efficacy Studies: The core service segment. Involves testing drug candidates in validated animal tumor models to demonstrate proof-of-concept, determine dose-response, and establish therapeutic windows.
-
Toxicology & Safety Pharmacology: Assessing on-target and off-target toxicities, maximum tolerated dose (MTD), and effects on major organ systems.
-
Bioanalysis & Pharmacokinetics/Pharmacodynamics (PK/PD): Measuring drug concentrations in blood/tissues over time and linking exposure to pharmacological effect.
-
Model Development & Validation: A high-value, differentiated service. Creating and characterizing novel, clinically relevant animal models, including complex genetically engineered mouse models (GEMMs), humanized immune system models, and patient-derived xenografts (PDXs).
-
Translational & Biomarker Services: Identifying predictive biomarkers, conducting imaging studies (e.g., MRI, PET in rodents), and performing correlative analyses to bridge preclinical findings to clinical trial design.
By Model Type & Complexity:
-
Syngeneic Models: Tumors derived from the same genetic background as the host mouse; used to study immuno-oncology (IO) therapies in an intact immune system. High-demand segment.
-
Xenograft Models:
-
Cell Line-Derived Xenografts (CDX): Standard models using established human cancer cell lines. Cost-effective for high-throughput screening.
-
Patient-Derived Xenografts (PDX): Fastest-growing, high-fidelity segment. Tumors implanted directly from patient biopsies, better preserving tumor heterogeneity and stroma. Critical for translational research and co-clinical trials.
-
-
Genetically Engineered Mouse Models (GEMMs): Models that spontaneously develop tumors due to genetic alterations, mimicking human cancer progression and microenvironment.
-
Humanized Mouse Models: Immunodeficient mice engrafted with human immune cells (hematopoietic stem cells, PBMCs) or tumors. Essential for evaluating human-specific immunotherapies (e.g., T-cell engagers, checkpoint inhibitors).
By Therapeutic Modality (High-Growth Niches):
-
Immuno-Oncology (IO): The largest and most dynamic segment, requiring specialized syngeneic and humanized models.
-
Cell & Gene Therapies: Requiring complex models for evaluating CAR-T, TCR, and oncolytic virus therapies.
-
Antibody-Drug Conjugates (ADCs) & Bispecifics: Requiring models expressing specific tumor antigens.
-
Targeted Therapies & Small Molecules: For kinase inhibitors, PARP inhibitors, etc.
2. Key Players
The market includes large, diversified global CROs and specialized oncology-focused providers.
Leading Companies:
-
Charles River Laboratories International, Inc. (Global leader with comprehensive oncology capabilities)
-
Laboratory Corporation of America Holdings (Labcorp) (Via Covance Drug Development)
-
ICON plc (Broad CRO with strong preclinical units)
-
WuXi AppTec (Integrated global platform with strong in vivo biology)
-
Eurofins Scientific (Via its Discovery Services segment)
-
Crown Bioscience Inc. (a JSR Life Sciences company) – (Leader in PDX and translational oncology models)
-
The Jackson Laboratory (Non-profit leader in GEMMs and model generation)
-
Champion Oncology, Inc. (Specialized in PDX models and personalized oncology platforms)
-
Envigo (A leading research models and services provider)
-
Taconic Biosciences, Inc. (Specialized in genetically engineered and humanized mouse models)
-
MI Bioresearch, Inc. (formerly Molecular Imaging)
-
Pharmatest Services Ltd. (Specialized in bone metastasis and other niche models)
-
Oncodesign Services (Preclinical oncology and PK/PD)
-
Xentech (Specialized in oncology pharmacology, part of Institut Curie)
-
Explora BioLabs (Specialized in in vivo study execution and model development)
-
Bioduro-Sundia (Integrated China/US platform)
3. Regional Analysis
-
North America: The largest market, particularly the United States. Driven by the highest concentration of biotech/pharma R&D spending, a dense network of academic cancer centers, and the presence of major global CROs. Strong demand for complex, innovative models.
-
Europe: A major market with strong academic research and pharmaceutical industry. The UK, Germany, and France are key hubs. Growth is supported by EU-wide cancer initiatives and collaborative research networks.
-
Asia-Pacific: The fastest-growing regional market. China is the epicenter of growth, fueled by massive government and private investment in biopharma R&D, an increasingly innovative domestic pipeline, and the rise of regional CROs (e.g., WuXi, CrownBio). Japan and South Korea are also significant markets.
-
Rest of the World: Emerging markets with limited but growing preclinical research activity, often serviced by global CROs establishing local footprints or through partnerships.
4. Porter’s Five Forces Analysis
-
Competitive Rivalry (High): The market is competitive, with large, full-service CROs competing against highly specialized oncology boutiques. Competition is based on scientific reputation, model portfolio (especially access to unique PDX/GEMM libraries), data quality, and turnaround time.
-
Bargaining Power of Suppliers (Low to Moderate): Suppliers provide laboratory animals (specialized mouse strains), cages, feed, and instrumentation. For proprietary, genetically engineered animal strains (e.g., from JAX, Taconic), supplier power is moderate to high.
-
Bargaining Power of Buyers (High): Buyers are pharmaceutical and biotechnology companies with significant R&D budgets. They are sophisticated and demand high-quality, reproducible data. They can multi-source projects and negotiate on price, especially for standard CDX studies.
-
Threat of New Entrants (Moderate): Barriers are significant due to the need for specialized scientific expertise, AAALAC-accredited animal facilities, deep experience with complex models, and a strong reputation for quality. However, spin-offs from academia or niche specialists can enter with unique model IP.
-
Threat of Substitutes (Low to Moderate): In vitro (2D/3D cell culture, organoids) and in silico (AI/ML) methods are complementary but not yet substitutes for the systemic, physiological context provided by in vivo studies, which remain a regulatory requirement. Their growth may moderate the growth rate of certain standard in vivo services.
5. SWOT Analysis
-
Strengths: Essential for regulatory approval of new drugs; provides critical translational insights; allows access to specialized expertise and expensive infrastructure without capital investment for sponsors; highly adaptable to new scientific trends.
-
Weaknesses: High operational costs (animal husbandry, compliance); ethical and public scrutiny around animal research; long study timelines; inherent biological variability in animal models.
-
Opportunities: Explosive growth of complex therapeutic modalities (IO, cell therapy) requiring sophisticated models; expansion in Asia-Pacific; development of "clinical trial in a mouse" (avatar/co-clinical) studies using PDX platforms; offering integrated data packages with bioinformatics.
-
Threats: Increasing regulatory and animal welfare compliance costs; advancements in human-relevant in vitro models (organ-on-a-chip, complex co-cultures) potentially replacing some exploratory in vivo work; economic downturns reducing biotech R&D funding.
6. Trend Analysis, Drivers & Challenges
Key Trends:
-
Rise of the "Clinical Trial in a Mouse" (Co-Clinical/ Avatar Trials): Using large PDX or GEMM cohorts to predict patient response, guide clinical trial design, and identify resistance mechanisms.
-
Humanization & Microbiome Integration: Developing more physiologically relevant models with human immune systems and defined microbiomes to better recapitulate the human tumor-immune axis and therapy response.
-
Multi-Omics & Digital Pathology Integration: Correlating in vivo efficacy with deep molecular profiling (genomics, transcriptomics) and AI-driven digital histopathology analysis.
-
Focus on Metastasis & Tumor Microenvironment (TME): Moving beyond subcutaneous tumors to orthotopic and metastatic models that better mimic disease progression and TME interactions.
Primary Drivers:
-
Unabated Growth of the Oncology Drug Pipeline: Oncology remains the largest therapeutic area for R&D, with thousands of molecules in development requiring preclinical testing.
-
Complexity of Novel Therapeutic Modalities: Cell therapies, gene therapies, and complex biologics require highly specialized and often customized in vivo testing platforms.
-
Biopharma's Outsourcing & FTE Reduction Strategy: A sustained trend to improve R&D efficiency and access external innovation.
-
Demand for Translational Relevance: Sponsors seek CROs that can provide data with a clearer line of sight to clinical success, driving demand for PDX and other high-fidelity models.
Critical Challenges:
-
High Cost and Time Intensity: Preclinical oncology studies are expensive and slow, creating pressure on CROs to improve operational efficiency.
-
Model Predictive Value & Translational Gaps: Despite advances, failures in translating animal efficacy to human clinical success remain a fundamental challenge and reputational risk.
-
Talent Acquisition & Retention: Severe competition for skilled in vivo pharmacologists, study directors, and veterinary pathologists.
-
Animal Welfare & Ethical Compliance: Increasing public and regulatory scrutiny necessitates transparent operations and investment in alternatives where possible (3Rs principle).
7. Value Chain Analysis
-
Model Development & IP Creation: The foundational step—developing, validating, and maintaining proprietary animal model colonies (PDX libraries, GEMMs, humanized models). This is a key source of differentiation.
-
Study Design & Protocol Development: Collaborative phase with the sponsor to design scientifically robust, regulatory-compliant studies.
-
In Vivo Study Execution: The core operational phase—animal husbandry, dosing, tumor measurement, clinical observations, and sample collection.
-
Ex Vivo & Bioanalytical Analysis: Processing of tissues/blood for histopathology, molecular analysis, flow cytometry, and PK/bioanalysis.
-
Data Management, Analysis & Reporting: Statistical analysis, interpretation, and compilation of a final study report.
-
Regulatory Consultation & Submission Support: Assisting sponsors in preparing preclinical sections for IND/CTA filings.
-
Follow-on & Translational Services: Additional biomarker analysis, mechanism of action studies, or combination therapy experiments.
Maximum value is captured by CROs that control proprietary, high-demand model systems (Step 1) and offer integrated, end-to-end services with deep data insights (Steps 5-7), moving beyond mere fee-for-service study execution.
8. Quick Recommendations for Stakeholders
-
For Oncology-Focused CROs (CrownBio, Champion, Xentech): Double down on your unique model IP. Continuously expand and characterize your PDX/GEMM libraries. Develop branded, standardized study platforms ("IO platform," "metastasis platform") to reduce sponsor study start-up time. Build strong bioinformatics and data science teams to deliver insights, not just data.
-
For Large, Diversified CROs (Charles River, Labcorp, WuXi): Leverage your scale and broad therapeutic expertise to offer integrated packages (e.g., in vivo + DMPK + toxicology). Acquire or partner with specialized oncology boutiques to gain access to cutting-edge model technology. Invest in automating routine in vivo tasks to improve margins and reproducibility.
-
For Biopharma Sponsors: Select CRO partners based on specific model and modality expertise, not just general reputation. Engage CROs early in the discovery process for collaborative model selection and study design. Consider strategic partnerships or preferred provider agreements with CROs that have unique model assets critical to your pipeline.
-
For Investors: Focus on CROs with defensible IP in high-fidelity model systems (especially PDX and complex humanized models) and a strong presence in the high-growth Asia-Pacific market. The business model of selling access to proprietary model libraries alongside study services is highly attractive. Monitor CROs that are successfully integrating AI and multi-omics into their service offerings.
-
For New Entrants/Academic Spin-offs: The barrier is high. Success requires a clearly differentiated, patent-protected model technology addressing a major unmet need in preclinical oncology (e.g., a novel metastasis model, a model for a rare cancer). A partnership or eventual acquisition by a larger CRO is a likely exit strategy.
Report Basis: History Years: 2020-2024; Base Year: 2025; Forecast Period: 2026-2036.
Note: All market values (XX, YY) and CAGR (Z%) are illustrative placeholders. This analysis reflects the specialized and scientifically driven nature of preclinical CRO services. Customized data, including modality-specific demand forecasts, pricing analysis, and detailed competitive capability matrices, is available per client specifications.
Table of Contents
Global Oncology Based In-vivo CRO global market
1 Industry Overview of Oncology Based In-vivo CRO
1.1 Oncology Based In-vivo CRO Market Overview
1.1.1 Oncology Based In-vivo CRO Product Scope
1.1.2 Market Status and Outlook
1.2 Global Oncology Based In-vivo CRO Market Size and Analysis by Regions ()
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Oncology Based In-vivo CRO Market by Type
1.3.1 Blood cancer
1.3.2 Solid tumors
1.3.3 Other
1.4 Oncology Based In-vivo CRO Market by End Users/Application
1.4.1 Hospitals
1.4.2 Rehabilitation Centers
1.4.3 Others
2 Global Oncology Based In-vivo CRO Competition Analysis by Players
2.1 Oncology Based In-vivo CRO Market Size (Value) by Players ()
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
3 Company (Top Players) Profiles
3.1 Crown Bioscience
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.2 Charles River Laboratory
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.3 ICON Plc.
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.4 Eurofins Scientific
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.5 Taconic Biosciences
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.6 Covance
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.7 EVOTEC
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.8 The Jackson Laboratory
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.9 Wuxi AppTec.
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.10 MI Bioresearch, Inc.
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Oncology Based In-vivo CRO Revenue (Million USD) ()
3.11 Living Tumor Laboratory
3.12 Champion Oncology, Inc.
3.13 Xentech
4 Global Oncology Based In-vivo CRO Market Size by Type and Application ()
4.1 Global Oncology Based In-vivo CRO Market Size by Type ()
4.2 Global Oncology Based In-vivo CRO Market Size by Application ()
4.3 Potential Application of Oncology Based In-vivo CRO in Future
4.4 Top Consumer/End Users of Oncology Based In-vivo CRO
5 United States Oncology Based In-vivo CRO Development Status and Outlook
5.1 United States Oncology Based In-vivo CRO Market Size ()
5.2 United States Oncology Based In-vivo CRO Market Size and Market Share by Players ()
5.3 United States Oncology Based In-vivo CRO Market Size by Application ()
6 Europe Oncology Based In-vivo CRO Development Status and Outlook
6.1 Europe Oncology Based In-vivo CRO Market Size ()
6.2 Europe Oncology Based In-vivo CRO Market Size and Market Share by Players ()
6.3 Europe Oncology Based In-vivo CRO Market Size by Application ()
7 China Oncology Based In-vivo CRO Development Status and Outlook
7.1 China Oncology Based In-vivo CRO Market Size ()
7.2 China Oncology Based In-vivo CRO Market Size and Market Share by Players ()
7.3 China Oncology Based In-vivo CRO Market Size by Application ()
8 Japan Oncology Based In-vivo CRO Development Status and Outlook
8.1 Japan Oncology Based In-vivo CRO Market Size ()
8.2 Japan Oncology Based In-vivo CRO Market Size and Market Share by Players ()
8.3 Japan Oncology Based In-vivo CRO Market Size by Application ()
9 Southeast Asia Oncology Based In-vivo CRO Development Status and Outlook
9.1 Southeast Asia Oncology Based In-vivo CRO Market Size ()
9.2 Southeast Asia Oncology Based In-vivo CRO Market Size and Market Share by Players ()
9.3 Southeast Asia Oncology Based In-vivo CRO Market Size by Application ()
10 India Oncology Based In-vivo CRO Development Status and Outlook
10.1 India Oncology Based In-vivo CRO Market Size ()
10.2 India Oncology Based In-vivo CRO Market Size and Market Share by Players ()
10.3 India Oncology Based In-vivo CRO Market Size by Application ()
11 Market Forecast by Regions, Type and Application ()
11.1 Global Oncology Based In-vivo CRO Market Size (Value) by Regions ()
11.1.1 United States Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.1.2 Europe Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.1.3 China Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.1.4 Japan Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.1.5 Southeast Asia Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.1.6 India Oncology Based In-vivo CRO Revenue and Growth Rate ()
11.2 Global Oncology Based In-vivo CRO Market Size (Value) by Type ()
11.3 Global Oncology Based In-vivo CRO Market Size by Application ()
12 Oncology Based In-vivo CRO Market Dynamics
12.1 Oncology Based In-vivo CRO Market Opportunities
12.2 Oncology Based In-vivo CRO Challenge and Risk
12.2.1 Competition from Opponents
12.2.2 Downside Risks of Economy
12.3 Oncology Based In-vivo CRO Market Constraints and Threat
12.3.1 Threat from Substitute
12.3.2 Government Policy
12.3.3 Technology Risks
12.4 Oncology Based In-vivo CRO Market Driving Force
12.4.1 Growing Demand from Emerging Markets
12.4.2 Potential Application
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
13.3.1 Economic Fluctuations
13.3.2 Other Risk Factors
14 Research Finding/Conclusion
15 Appendix
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Global Oncology Based In-vivo CRO Market Size (Million USD) Status and Outlook ()
Table Global Oncology Based In-vivo CRO Revenue (Million USD) Comparison by Regions ()
Figure Global Oncology Based In-vivo CRO Market Share by Regions ()
Figure United States Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Figure Europe Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Figure China Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Figure Japan Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Figure Southeast Asia Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Figure India Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate by Regions ()
Table Global Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate (%) Comparison by Product ()
Figure Global Oncology Based In-vivo CRO Revenue Market Share by Type in 2017
Figure Blood cancer Market Size (Million USD) and Growth Rate ()
Figure Solid tumors Market Size (Million USD) and Growth Rate ()
Figure Other Market Size (Million USD) and Growth Rate ()
Figure Global Oncology Based In-vivo CRO Market Share by Application in 2017
Figure Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate in Hospitals ()
Figure Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate in Rehabilitation Centers ()
Figure Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate in Others ()
Table Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table Crown Bioscience Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Crown Bioscience ()
Figure Crown Bioscience Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Charles River Laboratory Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Charles River Laboratory ()
Figure Charles River Laboratory Oncology Based In-vivo CRO Business Revenue Market Share ()
Table ICON Plc. Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of ICON Plc. ()
Figure ICON Plc. Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Eurofins Scientific Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Eurofins Scientific ()
Figure Eurofins Scientific Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Taconic Biosciences Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Taconic Biosciences ()
Figure Taconic Biosciences Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Covance Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Covance ()
Figure Covance Oncology Based In-vivo CRO Business Revenue Market Share ()
Table EVOTEC Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of EVOTEC ()
Figure EVOTEC Oncology Based In-vivo CRO Business Revenue Market Share ()
Table The Jackson Laboratory Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of The Jackson Laboratory ()
Figure The Jackson Laboratory Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Wuxi AppTec. Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Wuxi AppTec. ()
Figure Wuxi AppTec. Oncology Based In-vivo CRO Business Revenue Market Share ()
Table MI Bioresearch, Inc. Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of MI Bioresearch, Inc. ()
Figure MI Bioresearch, Inc. Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Living Tumor Laboratory Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Living Tumor Laboratory ()
Figure Living Tumor Laboratory Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Champion Oncology, Inc. Basic Information List
Table Oncology Based In-vivo CRO Business Revenue (Million USD) of Champion Oncology, Inc. ()
Figure Champion Oncology, Inc. Oncology Based In-vivo CRO Business Revenue Market Share ()
Table Xentech Basic Information List
Table Global Oncology Based In-vivo CRO Market Size (Million USD) by Product ()
Figure Global Oncology Based In-vivo CRO Revenue Market Share (%) by Product ()
Figure Global Oncology Based In-vivo CRO Market Share by Product in 2017
Table Global Oncology Based In-vivo CRO Market Size by Application ()
Figure Global Oncology Based In-vivo CRO Revenue Market Share (%) by Application in 2017
Table Top Consumer/End Users of Oncology Based In-vivo CRO
Figure United States Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table United States Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure United States Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure United States Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table United States Oncology Based In-vivo CRO Market Size by Application ()
Figure United States Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure United States Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure Europe Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table Europe Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure Europe Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure Europe Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table Europe Oncology Based In-vivo CRO Market Size by Application ()
Figure Europe Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure Europe Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure China Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table China Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure China Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure China Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table China Oncology Based In-vivo CRO Market Size by Application ()
Figure China Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure China Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure Japan Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table Japan Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure Japan Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure Japan Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table Japan Oncology Based In-vivo CRO Market Size by Application ()
Figure Japan Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure Japan Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure Southeast Asia Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table Southeast Asia Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure Southeast Asia Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure Southeast Asia Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table Southeast Asia Oncology Based In-vivo CRO Market Size by Application ()
Figure Southeast Asia Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure Southeast Asia Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure India Oncology Based In-vivo CRO Market Size (Million USD) and Growth Rate ()
Table India Oncology Based In-vivo CRO Market Size (Million USD) by Players ()
Figure India Oncology Based In-vivo CRO Market Size Share by Players in 2013
Figure India Oncology Based In-vivo CRO Market Size Share by Players in 2017
Table India Oncology Based In-vivo CRO Market Size by Application ()
Figure India Oncology Based In-vivo CRO Revenue Market Share (%) by Application ()
Figure India Oncology Based In-vivo CRO Market Size Share by Application in 2017
Figure Global Oncology Based In-vivo CRO Market Size and Growth Rate ()
Table Global Oncology Based In-vivo CRO Market Size (Million USD) by Regions ()
Figure Global Oncology Based In-vivo CRO Market Size Share ()
Figure Global Oncology Based In-vivo CRO Market Size Share by Regions in 2025
Figure United States Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Figure Europe Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Figure China Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Figure Japan Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Figure Southeast Asia Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Figure India Oncology Based In-vivo CRO Revenue (Million USD) and Growth Rate ()
Table Global Oncology Based In-vivo CRO Market Size (Million USD) by Type ()
Figure Global Oncology Based In-vivo CRO Market Size Share by Type in 2018
Figure Global Oncology Based In-vivo CRO Market Size Share by Type in 2025
Table Global Oncology Based In-vivo CRO Market Size (Million USD) by Application ()
Figure Global Oncology Based In-vivo CRO Market Size (Million USD) by Application in 2018
1. Segments Analysis
By Service Type:
-
Pharmacology & Efficacy Studies: The core service segment. Involves testing drug candidates in validated animal tumor models to demonstrate proof-of-concept, determine dose-response, and establish therapeutic windows.
-
Toxicology & Safety Pharmacology: Assessing on-target and off-target toxicities, maximum tolerated dose (MTD), and effects on major organ systems.
-
Bioanalysis & Pharmacokinetics/Pharmacodynamics (PK/PD): Measuring drug concentrations in blood/tissues over time and linking exposure to pharmacological effect.
-
Model Development & Validation: A high-value, differentiated service. Creating and characterizing novel, clinically relevant animal models, including complex genetically engineered mouse models (GEMMs), humanized immune system models, and patient-derived xenografts (PDXs).
-
Translational & Biomarker Services: Identifying predictive biomarkers, conducting imaging studies (e.g., MRI, PET in rodents), and performing correlative analyses to bridge preclinical findings to clinical trial design.
By Model Type & Complexity:
-
Syngeneic Models: Tumors derived from the same genetic background as the host mouse; used to study immuno-oncology (IO) therapies in an intact immune system. High-demand segment.
-
Xenograft Models:
-
Cell Line-Derived Xenografts (CDX): Standard models using established human cancer cell lines. Cost-effective for high-throughput screening.
-
Patient-Derived Xenografts (PDX): Fastest-growing, high-fidelity segment. Tumors implanted directly from patient biopsies, better preserving tumor heterogeneity and stroma. Critical for translational research and co-clinical trials.
-
-
Genetically Engineered Mouse Models (GEMMs): Models that spontaneously develop tumors due to genetic alterations, mimicking human cancer progression and microenvironment.
-
Humanized Mouse Models: Immunodeficient mice engrafted with human immune cells (hematopoietic stem cells, PBMCs) or tumors. Essential for evaluating human-specific immunotherapies (e.g., T-cell engagers, checkpoint inhibitors).
By Therapeutic Modality (High-Growth Niches):
-
Immuno-Oncology (IO): The largest and most dynamic segment, requiring specialized syngeneic and humanized models.
-
Cell & Gene Therapies: Requiring complex models for evaluating CAR-T, TCR, and oncolytic virus therapies.
-
Antibody-Drug Conjugates (ADCs) & Bispecifics: Requiring models expressing specific tumor antigens.
-
Targeted Therapies & Small Molecules: For kinase inhibitors, PARP inhibitors, etc.
2. Key Players
The market includes large, diversified global CROs and specialized oncology-focused providers.
Leading Companies:
-
Charles River Laboratories International, Inc. (Global leader with comprehensive oncology capabilities)
-
Laboratory Corporation of America Holdings (Labcorp) (Via Covance Drug Development)
-
ICON plc (Broad CRO with strong preclinical units)
-
WuXi AppTec (Integrated global platform with strong in vivo biology)
-
Eurofins Scientific (Via its Discovery Services segment)
-
Crown Bioscience Inc. (a JSR Life Sciences company) – (Leader in PDX and translational oncology models)
-
The Jackson Laboratory (Non-profit leader in GEMMs and model generation)
-
Champion Oncology, Inc. (Specialized in PDX models and personalized oncology platforms)
-
Envigo (A leading research models and services provider)
-
Taconic Biosciences, Inc. (Specialized in genetically engineered and humanized mouse models)
-
MI Bioresearch, Inc. (formerly Molecular Imaging)
-
Pharmatest Services Ltd. (Specialized in bone metastasis and other niche models)
-
Oncodesign Services (Preclinical oncology and PK/PD)
-
Xentech (Specialized in oncology pharmacology, part of Institut Curie)
-
Explora BioLabs (Specialized in in vivo study execution and model development)
-
Bioduro-Sundia (Integrated China/US platform)
